アブストラクト
| Title | 支持療法の最前線 |
|---|---|
| Subtitle | 特集1 気になるがん治療の最新Topics |
| Authors | 奥田泰考 |
| Authors (kana) | |
| Organization | 自治医科大学附属病院薬剤部 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 6 |
| Page | 1059-1064 |
| Year/Month | 2023 / 5 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●患者の主観的指標は重要であり, 症状にあわせてPRO-CTCAEを用いた評価を検討する. ●がん薬物療法によって引き起こされる悪心・嘔吐(CINV)に対して, 制吐薬適正使用ガイドラインを基本にしたうえで, 個別に支持療法を検討する. ●化学療法誘発性末梢神経障害(CIPN)に対する薬物療法は, 原因となる抗がん薬の特徴にあわせて支持療法薬を検討する. ●継続的なモニタリングにより免疫関連有害事象(irAE)の早期発見に努め, 診療科間の橋渡しを担う. ●継続的に栄養状態を評価し, がん悪液質を見逃すことなく支持療法を提案する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Balaban CD, et al : What is nausea? A historical analysis of changing views. Auton Neurosci, 202 : 5-17, 2017
- 2) Singh P, et al : Nausea : a review of pathophysiology and therapeutics. Therap Adv Gastroenterol, 9 : 98-112, 2016
- 3) 日本癌治療学会・編 : 制吐薬適正使用ガイドライン2015年10月第2版. 金原出版, 2015
- 4) Dranitsaris G, et al : The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol, 28 : 1260-1267, 2017
- 5) National Cancer Institute : NCI-PRO-CTCAE(R)ITEMS-JAPANESE. 2022(https://healthcaredelivery.cancer.gov/pro-ctcae/instruments/pro-ctcae/pro-ctcae_japanese.pdf)
残りの42件を表示する
- 6) Navari RM, et al : Olanzapine for the Prevention of Chemo-therapy-Induced Nausea and Vomiting. N Engl J Med, 375 : 134-142, 2016
- 7) Hashimoto H, et al : Olanzapine 5mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting(J-FORCE) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 21 : 242-249, 2020
- 8) Hata A, et al : Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting : CONSOLE. J Clin Oncol, 40 : 180-188, 2022
- 9) Lanzarotti C, et al : Effect of netupitant, a highly selective NK? receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer, 21 : 2783-2791, 2013
- 10) Nakamura M, et al : A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer(ESPRESSO-01). Oncologist, 22 : 592-600, 2017
- 11) Komatsu Y, et al : Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci, 106 : 891-895, 2015
- 12) Gu YL, et al : Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection : A systematic review and meta-analysis. Medicine(Baltimore), 98 : e17364, 2019
- 13) 「がんの社会学」に関する研究グループ : 2013がん体験者の悩みや負担等に関する実態調査報告書がんと向き合った4,054人の声. 静岡県立静岡がんセンター研究所, 2016
- 14) Seretny M, et al : Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy : A systematic review and meta-analysis. Pain, 155 : 2461-2470, 2014
- 15) Cavaletti G, et al : Chemotherapy-induced neuropathy. Curr Treat Options Neurol, 13 : 180-190, 2011
- 16) Smith EM, et al : The total neuropathy score : a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum, 35 : 96-102, 2008
- 17) Stubblefield MD, et al : A prospective surveillance model for physical rehabilitation of women with breast cancer : chemo-therapy-induced peripheral neuropathy. Cancer, 118(8 Suppl) : 2250-2260, 2012
- 18) Rowinsky EK, et al : The clinical pharmacology of paclitaxel(Taxol). Semin Oncol, 20(4 Suppl 3) : 16-25, 1993
- 19) Schneider BP, et al : Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res, 21 : 5082-5091, 2015
- 20) Cavaletti G, et al : Chemotherapy-induced neuropathy. Curr Treat Options Neurol, 13 : 180-190, 2011
- 21) Jordan B, et al ; ESMO Guidelines Committee : Systemic anticancer therapy-induced peripheral and central neuro-toxicity : ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol, 31 : 1306-1319, 2020
- 22) Kawashiri T, et al : L type Ca2+channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 over-expression in rats. Mol Pain, 8 : 7, 2012
- 23) Tournigand C, et al : OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol, 24 : 394-400, 2006
- 24) Smith EM, et al ; Alliance for Clinical Trials in Oncology : Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial. JAMA, 309 : 1359-1367, 2013
- 25) Loprinzi CL, et al : Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neuro toxicity(N08CB/Alliance). J Clin Oncol, 32 : 997-1005, 2014
- 26) Oki E, et al : Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy(GENIUS trial) : a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol, 20 : 767-775, 2015
- 27) Motoo Y, et al : Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy : a randomized, open-label, phase 2 trial(HOPE-2). Int J Clin Oncol, 25 : 1123-1129, 2020
- 28) Boyette-Davis JA, et al : Mechanisms involved in the develop-ment of chemotherapy-induced neuropathy. Pain Manag, 5 : 285-296, 2015
- 29) Gelderblom H, et al : Cremophor EL : the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 37 : 1590-1598, 2001
- 30) Sugimoto M, et al : Mirogabalin vs pregabalin for chemo-therapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer, 21 : 1319, 2021
- 31) 石川雄大, 他 : 抗がん薬に伴う末梢神経障害に対するミロガバリンの有効性評価. 医療薬学, 47 : 1-9, 2021
- 32) Hanai A, et al : Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy : Prospective Self-Controlled Trial. J Natl Cancer Inst, 110 : 141-148, 2018
- 33) Raschi E, et al : Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors : A Clinical Perspective from Pharmacovigilance. Target Oncol, 15 : 449-466, 2020
- 34) 埼玉がん薬物療法研究会 : irAE(免疫関連有害事象)対策手引書. 2020(http://ssop.umin.ne.jp/downroad.html#irae)
- 35) 日本臨床腫瘍学会・編 : がん免疫療法ガイドライン第2版. 金原出版, 2019
- 36) Fearon K, et al : Definition and classification of cancer cachexia : an international consensus. Lancet Oncol, 12 : 489-495, 2011
- 37) Sun H, et al : Cachexia is associated with depression, anxiety and quality of life in cancer patients. BMJ Support Palliat Care, bmjspcare-2019-002176, 2020
- 38) Porter S, et al : Cancer cachexia care : the contribution of qualitative research to evidence-based practice. Cancer Nurs, 35 : E30-38, 2012
- 39) Muscaritoli M, et al : Perspectives of health care professionals on cancer cachexia : results from three global surveys. Ann Oncol, 27 : 2230-2236, 2016
- 40) Shibata M, et al : A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer. Adv Ther, 37 : 5010-5022, 2020
- 41) Temel JS, et al : Anamorelin in patients with non-small-cell lung cancer and cachexia(ROMANA 1 and ROMANA 2) : results from two randomised, double-blind, phase 3 trials. Lancet Oncol, 17 : 519-531, 2016
- 42) Takayama K, et al : Anamorelin(ONO-7643)in Japanese patients with non-small cell lung cancer and cachexia : results of a randomized phase 2 trial. Support Care Cancer, 24 : 3495-3505, 2016
- 43) Katakami N, et al : Anamorelin(ONO-7643)for the treat ment of patients with non-small cell lung cancer and cachexia : Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients(ONO-7643-04). Cancer, 124 : 606-616, 2018
- 44) Naito T : Emerging Treatment Options For Cancer-Associated Cachexia : A Literature Review. Ther Clin Risk Manag, 15 : 1253-1266, 2019
- 45) Roeland EJ, et al : Management of Cancer Cachexia : ASCO Guideline. J Clin Oncol, 38 : 2438-2453, 2020
- 46) de van der Schueren MAE, et al : Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy : current evidence and guidance for design of future trials. Ann Oncol, 29 : 1141-1153, 2018
- 47) Iizumi S, et al : Survival impact of post-progression chemo-therapy in advanced gastric cancer : systematic review and meta-analysis. Cancer Chemother Pharmacol, 81 : 981-989, 2018
